Lazard Asset Management
ITCI

Lazard Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Lazard Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,567
Closed -$214K – 2622
2024
Q4 		$214K Sell
2,567
-196
-7% -$16.1K ﹤0.01% 1598
2024
Q3 		$201K Hold
2,763
– – ﹤0.01% 1610
2024
Q2 		$188K Buy
2,763
+1,766
+177% +$122K ﹤0.01% 1580
2024
Q1 		$68K Hold
997
– – ﹤0.01% 1654
2023
Q4 		$71K Hold
997
– – ﹤0.01% 1792
2023
Q3 		$51K Buy
997
+539
+118% +$31.4K ﹤0.01% 1850
2023
Q2 		$29K Buy
+458
New +$28.5K ﹤0.01% 2019
2021
Q4 		– Sell
-31,525
Closed -$1.18M – 2489
2021
Q3 		$1.18M Buy
+31,525
New +$1.1M ﹤0.01% 1037

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Lazard Asset Management's ITCI Position: Q1 2025 in Review

Lazard Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 2,567 shares — an estimated $214K sold.

Lazard Asset Management first reported a position in ITCI in Q3 2021 and held it in 8 quarters. The position peaked at $1.18M in Q3 2021. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Lazard Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 2,567 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $214K.
  • Lazard Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2021 and held it in 8 quarters.
  • Lazard Asset Management's Intra-Cellular Therapies Inc. position peaked at $1.18M in Q3 2021.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.